1-13 of 13
Steven J. Isakoff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer

Rachel O. Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden, Annika Putur, Elena Bitman, Win Thant, Ting Liu, Caroline Weipert, Geoffrey Fell, Laura M. Spring, Seth Wander, Beverly Moy, Neelima Vidula, Steven J. Isakoff, Andreas Varkaris, Dejan Juric, Ryan Corcoran, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-2771
Published: 02 January 2025
View article titled, TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
Open the PDF for TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Rebecca A. Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J. Wongchenko, Sarah-Jayne Reilly, Nicholas Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4329–4338.
https://doi.org/10.1158/1078-0432.CCR-24-0465
Published: 01 October 2024
View article titled, Ipatasertib plus Paclitaxel for Patients with <em>PIK3CA</em>/<em>AKT1</em>/<em>PTEN</em>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
Open the PDF for Ipatasertib plus Paclitaxel for Patients with <em>PIK3CA</em>/<em>AKT1</em>/<em>PTEN</em>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T. Coates, Bogang Wu, Rachel O. Abelman, Laura Spring, Beverly Moy, Phoebe Ryan, Mark N. Melkonyan, Ann Partridge, Dejan Juric, Jeffrey Peppercorn, Heather Parsons, Seth A. Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven J. Isakoff, Sara M. Tolaney, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2917–2924.
https://doi.org/10.1158/1078-0432.CCR-24-0428
Published: 15 July 2024
View article titled, Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas-Junior, Yeesoo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 767–778.
https://doi.org/10.1158/1078-0432.CCR-23-2084
Published: 16 February 2024
View article titled, First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Open the PDF for First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa I. Gallagher, Cristina Saura, Paolo G. Nuciforo, Isabel Calvo, Jay Andersen, José Luis Passos-Coelho, Miguel J. Gil-Gil, Begoña Bermejo, Debra A. Pratt, Eva M. Ciruelos, Patricia Villagrasa, Matthew J. Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 993–1003.
https://doi.org/10.1158/1078-0432.CCR-21-2498
Published: 01 March 2022
View article titled, Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Open the PDF for Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Siang-Boon Koh, Kenneth Ross, Steven J. Isakoff, Nsan Melkonjan, Lei He, Karina J. Matissek, Andrew Schultz, Erica L. Mayer, Tiffany A. Traina, Lisa A. Carey, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Adam Langenbucher, Srinivas Vinod Saladi, Sridhar Ramaswamy, Michael S. Lawrence, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4883–4897.
https://doi.org/10.1158/1078-0432.CCR-21-0714
Published: 01 September 2021
View article titled, RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Open the PDF for RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

Neelima Vidula, Taronish Dubash, Michael S. Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A. Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J. Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A. John Iafrate, Gad Getz, Lee Zou, Leif W. Ellisen, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4852–4862.
https://doi.org/10.1158/1078-0432.CCR-20-0638
Published: 15 September 2020
View article titled, Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Open the PDF for Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Laura M. Spring, Geoffrey Fell, Andrea Arfe, Chandni Sharma, Rachel Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2838–2848.
https://doi.org/10.1158/1078-0432.CCR-19-3492
Published: 15 June 2020
View article titled, Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Open the PDF for Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis in another window
Includes: Supplementary data
Journal Articles

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

Melinda L. Telli, Charles Chu, Sunil S. Badve, Shaveta Vinayak, Daniel P. Silver, Steven J. Isakoff, Virginia Kaklamani, William Gradishar, Vered Stearns, Roisin M. Connolly, James M. Ford, Joshua J. Gruber, Sylvia Adams, Judy Garber, Nadine Tung, Chris Neff, Ryan Bernhisel, Kirsten M. Timms, Andrea L. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2704–2710.
https://doi.org/10.1158/1078-0432.CCR-19-0664
Published: 01 June 2020
View article titled, Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Open the PDF for Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <em>BRCA1/2</em> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis in another window
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer
Open the PDF for <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)

Mark Jesus M. Magbanua, Hope S. Rugo, Denise M. Wolf, Louai Hauranieh, Ritu Roy, Praveen Pendyala, Eduardo V. Sosa, Janet H. Scott, Jin Sun Lee, Brandelyn Pitcher, Terry Hyslop, William T. Barry, Steven J. Isakoff, Maura Dickler, Laura van't Veer, John W. Park
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1486–1499.
https://doi.org/10.1158/1078-0432.CCR-17-2312
Published: 14 March 2018
View article titled, Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)
Open the PDF for Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) in another window
Includes: Supplementary data
Journal Articles

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid, Bryan Hennessy, Gordon B. Mills, Kristin C. Jensen, Zoltan Szallasi, William T. Barry, Eric P. Winer, Nadine M. Tung, Steven J. Isakoff, Paula D. Ryan, April Greene-Colozzi, Alexander Gutin, Zaina Sangale, Diana Iliev, Chris Neff, Victor Abkevich, Joshua T. Jones, Jerry S. Lanchbury, Anne-Renee Hartman, Judy E. Garber, James M. Ford, Daniel P. Silver, Andrea L. Richardson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3764–3773.
https://doi.org/10.1158/1078-0432.CCR-15-2477
Published: 31 July 2016
View article titled, Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Open the PDF for Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Ayca Gucalp, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero, Vered Stearns, Ashley S. Doane, Michael Danso, Mary Ellen Moynahan, Lamia F. Momen, Joseph M. Gonzalez, Arooj Akhtar, Dilip D. Giri, Sujata Patil, Kimberly N. Feigin, Clifford A. Hudis, Tiffany A. Traina
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5505–5512.
https://doi.org/10.1158/1078-0432.CCR-12-3327
Published: 01 October 2013
View article titled, Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Open the PDF for Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer in another window
Includes: Supplementary data